In 2004, the patient was started on continuous subcutaneous insulin therapy CSII using an external pump with insulin glulisine, but without evident benefits in terms of hyperglycemia control or reduction of the risk of diabetic ketoacidosis (DKA). The gene discussed is INS; the disease is Hyperglycemia.